Patient Profiles

Approximately 240 million people around the world are chronically infected with hepatitis B, and an estimated 780,000 of these people die each year from hepatitis B complications.1

Paul Dutton*

Age: 32

Location: Chicago, Illinois

Incident: During Paul's first day on the job as a police officer, he got a call that there was suspicious drug activity going on near a bar downtown. When Paul and his partner arrived on the scene, it was clear that arrests would need to be made. While making the arrest, Paul was accidentally stuck with a used needle by a suspect who got away. Paul remembered learning Centers for Disease Control and Prevention (CDC) Guidelines during his training and knew that getting stuck with a used needle left him exposed to potential viruses, including hepatitis B.

Diagnosis: When Paul arrived at the hospital, the attending physician noted that the patient had:

  • Not been previously vaccinated for hepatitis B
  • Come into contact with a used needle from an unidentified user

Treatment: The doctor administered the hepatitis B vaccine along with a hepatitis B immune globulin (HyperHEP B® S/D) [hepatitis B immune globulin (human)].

Outcome: Because Paul was treated immediately and finished his vaccination series within 6 months, he was protected from the hepatitis B virus.

The hepatitis B virus is 50 to 100 times more infectious than HIV.2

Madison Thomas*

Age: 27

Location: New York, New York

Incident: Madison is currently registered at a local college pursuing her graduate degree. After class, Madison went to a nearby club and met Owen, a singer in a band. They went on a few dates and had unprotected sex. She later found out that he was diagnosed with hepatitis B. Madison went to the CDC website and found out how serious her situation really was and how high her chances were contracting the same virus. Scared, she went to the hospital.

Diagnosis: When Madison arrived at the hospital, the attending physician noted that she had:

  • Not been previously vaccinated for hepatitis B
  • Come into sexual contact with a person who has hepatitis B

Treatment: The doctor administered HyperHEP B S/D.

Outcome: Because Madison was treated immediately and finished her vaccination series within 6 months; she was protected from the hepatitis B virus.

HyperHEP® B S/D (hepatitis B immune globulin [human]) is indicated for postexposure prophylaxis in the following situations: acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to an HBsAg-positive person, and household exposure to persons with acute HBV infection.

HyperHEP B S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Epinephrine should be available.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, hepatitis B immune globulin (human) should be given only if the expected benefits outweigh the risks.

Local pain and tenderness at the injection site, urticaria, and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immunoglobulin preparations. Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after hepatitis B immune globulin (human) administration.

HyperHEP B S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Please see HyperHEP S/D full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


References:

  1. World Health Organization (WHO). Hepatitis B fact sheet. WHO website. http://www.who.int/mediacentre/factsheets/fs204/en/. Updated July 2015. Accessed May 8, 2016.
  2. Centers for Disease Control and Prevention (CDC). Hepatitis B FAQs for the public. CDC website. http://www.cdc.gov/hepatitis/hbv/bfaq.htm. Updated October 23, 2015. Accessed May 8, 2016.